TEVA
Teva Pharmaceutical Industries Limited · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 151 | +7 | 369.28M | $12.48B | +9 | −1 |
| Q1 2026 | 146 | +3 | 327.68M | $9.78B | +10 | −8 |
| Q4 2025 | 144 | -1 | 326.44M | $10.18B | +3 | −3 |
| Q3 2025 | 23 | 0 | 176.53M | $3.56B | +1 | −2 |
| Q2 2025 | 21 | 0 | 197.53M | $3.31B | n/a | n/a |
| Q1 2025 | 18 | -3 | 84.56M | $1.30B | n/a | −3 |
| Q4 2024 | 21 | -1 | 89.79M | $1.98B | n/a | −1 |
| Q3 2024 | 21 | +2 | 78.93M | $1.23B | +2 | n/a |
| Q2 2024 | 19 | n/a | 61.88M | $1.01B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 12.13M | n/a | $197.08M | 0.2% | n/c | 1 | SEC ↗ |
| 2 | Glenview Capital ✦ | 9.16M | n/a | $148.81M | 3.2% | n/c | 1 | SEC ↗ |
| 3 | Renaissance Technologies ✦ | 8.73M | n/a | $141.84M | 0.2% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 8.50M | n/a | $137.52M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | D. E. Shaw & Co. ✦ | 5.89M | n/a | $95.63M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Arrowstreet Capital ✦ | 5.80M | n/a | $94.29M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Marshall Wace ✦ | 4.17M | n/a | $67.80M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 2.10M | n/a | $34.18M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 1.77M | n/a | $28.74M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Point72 Asset Management ✦ | 1.32M | n/a | $21.44M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Norges Bank ✦ (passive) | 1.07M | n/a | $17.45M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Greenlight Capital (DME Capital) ✦ | 324.85K | n/a | $5.28M | 0.3% | n/c | 1 | SEC ↗ ×2 |
| 13 | T. Rowe Price ✦ | 254.13K | n/a | $4.13M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Wellington Management ✦ | 186.21K | n/a | $3.03M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 15 | ARK Investment Management ✦ | 169.42K | n/a | $2.75M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 137.60K | n/a | $2.24M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | GAMCO Investors ✦ | 134.25K | n/a | $2.18M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Bridgewater Associates ✦ | 22.08K | n/a | $358,768 | 0.0% | n/c | 1 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 16.14K | n/a | $262,340 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 646 holders, 666.61M shares, $16.70B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.52K sh · $98,841
Director · 367.60K sh · $14.36M
Officer · 4.50K sh · $174,221
Officer · 314 sh · $12,153
Officer · 2.50K sh · $94,077
Director · 415 sh · $15,459
Officer · 6.95K sh · $261,224
Officer · 18.60K sh · $680,291
Director · 17 sh · $593
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology